Abstract:CDK9 is a member of the CDC2-like family of kinases. Its cyclin partners are members of the CYCLIN T family (T1, T2a, and T2b) and CYCLIN K. The CDK9/CYCLIN T1 complex is very important in the differentiation programme of several cell types, controlling specific differentiation pathways. Limited data are available regarding the expression of CDK9/CYCLIN T1 in haematopoietic and lymphoid tissues. The aim of this study was to analyse the expression of the CDK9/CYCLIN T1 complex in lymphoid tissue, in order to assess its role in B- and T-cell differentiation and lymphomagenesis. CDK9/CYCLIN T1 expression was found by immunohistochemistry in precursor B and T cells. In peripheral lymphoid tissues, germinal centre cells and scattered B- and T-cell blasts in interfollicular areas expressed CDK9/CYCLIN T1, while mantle cells, plasma cells, and small resting T-lymphocytes displayed no expression of either molecule. CDK9/CYCLIN T1 expression therefore appears to be related to particular stages of lymphoid differentiation/activation. CDK9 and CYCLIN T1 were highly expressed in lymphomas derived from precursor B and T cells, from germinal centre cells, such as follicular lymphomas, and from activated T cells (ie anaplastic large cell lymphomas). Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma also showed strong nuclear staining. Diffuse large B-cell, Burkitt's lymphomas, and peripheral T-cell lymphomas, among T-cell lymphoproliferative disorders, showed a wide range of values. No expression of CDK9 or CYCLIN T1 was detected in mantle cell and marginal zone lymphomas. However, at the mRNA level, an imbalance in the CDK9/CYCLIN T1 ratio was found in follicular lymphoma and diffuse large B-cell lymphomas with germinal centre phenotype, and in the cell lines of classical Hodgkin's lymphomas, Burkitt's lymphomas, and anaplastic large cell lymphoma, in comparison with reactive lymph nodes. These results suggest that the CDK9/CYCLIN T1 complex may affect the activation and differentiation programme of lymphoid cells. The molecular mechanism through which the CDK9/CYCLIN T1 complex is altered in malignant transformation needs to be elucidated.

New insight in cdk9 function: from Tat to MyoD.

Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX

Targeting cyclin-dependent kinase 9 in cancer therapy

Cdk9 phosphorylates p53 on serine 392 independently of CKII

CDK9 keeps RNA polymerase II on track

Targeting CDK9 for Anti-Cancer Therapeutics

Identification of novel CDK9 and Cyclin T1-associated protein complexes (CCAPs) whose siRNA depletion enhances HIV-1 Tat function

Cyclin-dependent kinase-9: an RNAPII kinase at the nexus of cardiac growth and death cascades

CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation

Targeted Degradation of CDK9 Potently Disrupts the MYC Transcriptional Network

CDK8 and CDK19: positive regulators of signal-induced transcription and negative regulators of Mediator complex proteins

CK1δ Activity is Modulated by CDK2/E- and CDK5/p35-mediated Phosphorylation

The CDK9-SPT5 axis in control of transcription elongation by RNAPII

Cyclin-dependent kinase 9 (Cdk9) of fission yeast is activated by the CDK-activating kinase Csk1, overlaps functionally with the TFIIH-associated kinase Mcs6, and associates with the mRNA cap methyltransferase Pcm1 in vivo

A Computational Study of Tat-CDK9-Cyclin Binding Dynamics and Its Implication in Transcription-Dependent HIV Latency.

Cdks, cyclins and CKIs: roles beyond cell cycle regulation

CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents

All-Atomic Molecular Dynamic Studies of Human and Drosophila CDK8: Insights into Their Kinase Domains, the LXXLL Motifs, and Drug Binding Site

Structural basis of Cdk7 activation by dual T-loop phosphorylation

DNA-Dependent Protein Kinase Catalytic Subunit (DNA-PKcs): Beyond the DNA Double-Strand Break Repair

Cyclin-dependent Kinase 9 Promotes Cervical Cancer Development Via AKT2/p53 Pathway.